Improving cancer therapy by targeting cancer stem cells: Directions, challenges, and clinical results

doi:10.5497/wjp.v4.i1.58

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7718)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

677

WORD

395

HTML

4334

Tables (1-2)

208

Sum=5614

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

940

Download

1164

Sum=2104

Mar 9, 2015 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Pharmacol. Mar 9, 2015; 4(1): 58-74
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.58

Table 2 Pathways and drug candidates targeting cancer stem cells

Pathway	Targets	Compounds	Clinical development
Hedgehog	Smoothened	¹Vismodegib[80-82]	Medulloblastoma
			Pancreatic cancer
			Hematological malignancies
Notch	γ-secretase	MK-0752[94]	Breast cancer
	DLL4	Demcizumab[88-90]	Pancreatic cancer
			NSCLC
			Ovarian cancer
		MEDI0639	Solid tumors
Wnt	β-catenin	Vantictumab[101]	Breast cancer
			Pancreatic cancer
			NSCLC
		OMP-54F28[102]	Ovarian cancer
			Pancreatic cancer
			Hepatic cancer
CXCR1/2-CXCL8	CXCR1	Reparixin[113,114]	Breast cancer
		SCH563705
	CXCR1/2
IL-6/JAK/STAT3	IL-6	²Tocilizumab
	JAK1, JAK2	³Tofacitinib
		⁴Chloroquine	Breast cancer[57]

¹Erivedge™, FDA and EMA approved for metastatic or locally advanced basal cell carcinoma;

²RoActemra™, FDA and EMA approved for rheumatoid arthritis;

³Xeljanz™, FDA approved for rheumatoid arthritis;

⁴FDA approved for malaria and extraintestinal amebiasis. DLL4: Delta-like ligand 4; FDA: Food and Drug Administration; NSCLC: Non-small-cell lung carcinoma; CXCR1/2-CXCL8: CXC chemokine receptor 1/2-interleukin 8; IL-6/JAK/STAT3: Interleukin 6/Janus kinase 2/Signal transducer and activator of transcription 3.

Citation: Ruffini PA, Vaja V, Allegretti M. Improving cancer therapy by targeting cancer stem cells: Directions, challenges, and clinical results. World J Pharmacol 2015; 4(1): 58-74
URL: https://www.wjgnet.com/2220-3192/full/v4/i1/58.htm
DOI: https://dx.doi.org/10.5497/wjp.v4.i1.58